Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)
      QxMD      Google Scholar   
Citation:
Pharmacogenet Genomics vol 26 (3) 133-137
Year:
2016
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
5
Parents:
2208  
Children:
None
Program:
TRP
Primary Committee:
Correl Sci NOS
Sec. Committees:
GI    
Pharmas:
 
Grants:
U10 CA180868, UG1 CA189867, R01CA062164, U10CA31946, R01CA116964, U10 CA180835, U10 CA031946, U10 CA033601, K05CA142885, U10 CA180821, U24 CA114740, U10 CA180850, R01 CA116964, U10 CA180790, P30 CA015083, U10CA33601, U24CA114740, R01 CA062164, U10 CA180867, K05 CA142885, U10 CA180888  
Corr. Author:
 
Authors:
                               
Networks:
HAWAII, LAPS-IL057, LAPS-MN026, LAPS-OH007, MCRC, MS012   
Study
NCCTG-N0147
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
dihydropyrimidine dehydrogenase, polymorphism, pharmacogenetics, 5-fluorouracil, colon cancer, toxicity